Literature DB >> 20651288

Identification of a novel macrophage phenotype that develops in response to atherogenic phospholipids via Nrf2.

Alexandra Kadl1, Akshaya K Meher, Poonam R Sharma, Monica Y Lee, Amanda C Doran, Scott R Johnstone, Michael R Elliott, Florian Gruber, Jenny Han, Wenshu Chen, Thomas Kensler, Kodi S Ravichandran, Brant E Isakson, Brian R Wamhoff, Norbert Leitinger.   

Abstract

RATIONALE: Macrophages change their phenotype and biological functions depending on the microenvironment. In atherosclerosis, oxidative tissue damage accompanies chronic inflammation; however, macrophage phenotypic changes in response to oxidatively modified molecules are not known.
OBJECTIVE: To examine macrophage phenotypic changes in response to oxidized phospholipids that are present in atherosclerotic lesions. METHODS AND
RESULTS: We show that oxidized phospholipid-treated murine macrophages develop into a novel phenotype (Mox) that is strikingly different from the conventional M1 and M2 macrophage phenotypes. Compared to M1 and M2, Mox macrophages show a different gene expression pattern, as well as decreased phagocytotic and chemotactic capacity. Treatment with oxidized phospholipids induces both M1 and M2 macrophages to switch to the Mox phenotype. Whole-genome expression array analysis and subsequent gene ontology clustering revealed that the Mox phenotype was characterized by abundant overrepresentation of Nrf2-mediated expression of redox-regulatory genes. In macrophages isolated from Nrf2(-/-) mice, oxidized phospholipid-induced gene expression and regulation of redox status were compromised. Moreover, we found that Mox macrophages comprise 30% of all macrophages in advanced atherosclerotic lesions of low-density lipoprotein receptor knockout (LDLR(-/-)) mice.
CONCLUSIONS: Together, we identify Nrf2 as a key regulator in the formation of a novel macrophage phenotype (Mox) that develops in response to oxidative tissue damage. The unique biological properties of Mox macrophages suggest this phenotype may play an important role in atherosclerotic lesion development as well as in other settings of chronic inflammation.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20651288      PMCID: PMC2941538          DOI: 10.1161/CIRCRESAHA.109.215715

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  64 in total

1.  PPARgamma activation primes human monocytes into alternative M2 macrophages with anti-inflammatory properties.

Authors:  M Amine Bouhlel; Bruno Derudas; Elena Rigamonti; Rébecca Dièvart; John Brozek; Stéphan Haulon; Christophe Zawadzki; Brigitte Jude; Gérard Torpier; Nikolaus Marx; Bart Staels; Giulia Chinetti-Gbaguidi
Journal:  Cell Metab       Date:  2007-08       Impact factor: 27.287

Review 2.  Alternative activation of macrophages: an immunologic functional perspective.

Authors:  Fernando O Martinez; Laura Helming; Siamon Gordon
Journal:  Annu Rev Immunol       Date:  2009       Impact factor: 28.527

3.  Structural identification of a novel pro-inflammatory epoxyisoprostane phospholipid in mildly oxidized low density lipoprotein.

Authors:  A D Watson; G Subbanagounder; D S Welsbie; K F Faull; M Navab; M E Jung; A M Fogelman; J A Berliner
Journal:  J Biol Chem       Date:  1999-08-27       Impact factor: 5.157

Review 4.  Nrf2 as a target for cancer chemoprevention.

Authors:  Xiang Yu; Thomas Kensler
Journal:  Mutat Res       Date:  2005-07-28       Impact factor: 2.433

5.  Regulation of LPS induced IL-12 production by IFN-gamma and IL-4 through intracellular glutathione status in human alveolar macrophages.

Authors:  K Dobashi; M Aihara; T Araki; Y Shimizu; M Utsugi; K Iizuka; Y Murata; J Hamuro; T Nakazawa; M Mori
Journal:  Clin Exp Immunol       Date:  2001-05       Impact factor: 4.330

6.  Functional polymorphisms in the transcription factor NRF2 in humans increase the risk of acute lung injury.

Authors:  Jacqui M Marzec; Jason D Christie; Sekhar P Reddy; Anne E Jedlicka; Hue Vuong; Paul N Lanken; Richard Aplenc; Tae Yamamoto; Masayuki Yamamoto; Hye-Youn Cho; Steven R Kleeberger
Journal:  FASEB J       Date:  2007-03-23       Impact factor: 5.191

7.  Microarray analysis reveals overexpression of CD163 and HO-1 in symptomatic carotid plaques.

Authors:  Petra Ijäs; Krista Nuotio; Jani Saksi; Lauri Soinne; Eija Saimanen; Marja-Liisa Karjalainen-Lindsberg; Oili Salonen; Seppo Sarna; Jarno Tuimala; Petri T Kovanen; Markku Kaste; Perttu J Lindsberg
Journal:  Arterioscler Thromb Vasc Biol       Date:  2006-11-09       Impact factor: 8.311

Review 8.  Activation of Nrf2-antioxidant signaling attenuates NFkappaB-inflammatory response and elicits apoptosis.

Authors:  Wenge Li; Tin Oo Khor; Changjiang Xu; Guoxiang Shen; Woo-Sik Jeong; Siwang Yu; Ah-Ng Kong
Journal:  Biochem Pharmacol       Date:  2008-07-23       Impact factor: 5.858

9.  Induction of CCR2-dependent macrophage accumulation by oxidized phospholipids in the air-pouch model of inflammation.

Authors:  Alexandra Kadl; Elena Galkina; Norbert Leitinger
Journal:  Arthritis Rheum       Date:  2009-05

10.  Lymphocyte recruitment into the aortic wall before and during development of atherosclerosis is partially L-selectin dependent.

Authors:  Elena Galkina; Alexandra Kadl; John Sanders; Danielle Varughese; Ian J Sarembock; Klaus Ley
Journal:  J Exp Med       Date:  2006-05-08       Impact factor: 14.307

View more
  220 in total

Review 1.  Modulation of oxidative stress, inflammation, and atherosclerosis by lipoprotein-associated phospholipase A2.

Authors:  Robert S Rosenson; Diana M Stafforini
Journal:  J Lipid Res       Date:  2012-06-04       Impact factor: 5.922

Review 2.  Macrophage subsets in atherosclerosis.

Authors:  Giulia Chinetti-Gbaguidi; Sophie Colin; Bart Staels
Journal:  Nat Rev Cardiol       Date:  2014-11-04       Impact factor: 32.419

3.  Nrf2 deficiency in myeloid cells is not sufficient to protect mice from high-fat diet-induced adipose tissue inflammation and insulin resistance.

Authors:  Akshaya K Meher; Poonam R Sharma; Vitor A Lira; Masayuki Yamamoto; Thomas W Kensler; Zhen Yan; Norbert Leitinger
Journal:  Free Radic Biol Med       Date:  2012-02-24       Impact factor: 7.376

4.  Expression of pannexin isoforms in the systemic murine arterial network.

Authors:  Alexander W Lohman; Marie Billaud; Adam C Straub; Scott R Johnstone; Angela K Best; Monica Lee; Kevin Barr; Silvia Penuela; Dale W Laird; Brant E Isakson
Journal:  J Vasc Res       Date:  2012-06-26       Impact factor: 1.934

Review 5.  Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm.

Authors:  Subhra K Biswas; Alberto Mantovani
Journal:  Nat Immunol       Date:  2010-09-20       Impact factor: 25.606

6.  Reductive metabolism increases the proinflammatory activity of aldehyde phospholipids.

Authors:  Elena Vladykovskaya; Evgeny Ozhegov; J David Hoetker; Zhengzhi Xie; Yonis Ahmed; Jill Suttles; Sanjay Srivastava; Aruni Bhatnagar; Oleg A Barski
Journal:  J Lipid Res       Date:  2011-09-27       Impact factor: 5.922

Review 7.  Macrophage polarization in pathology.

Authors:  Antonio Sica; Marco Erreni; Paola Allavena; Chiara Porta
Journal:  Cell Mol Life Sci       Date:  2015-07-26       Impact factor: 9.261

8.  Pivotal role of NOD2 in inflammatory processes affecting atherosclerosis and periodontal bone loss.

Authors:  Huaiping Yuan; Sami Zelkha; Sami Zelka; Marina Burkatovskaya; Rohit Gupte; Susan E Leeman; Salomon Amar
Journal:  Proc Natl Acad Sci U S A       Date:  2013-12-09       Impact factor: 11.205

Review 9.  From proliferation to proliferation: monocyte lineage comes full circle.

Authors:  Filip K Swirski; Ingo Hilgendorf; Clinton S Robbins
Journal:  Semin Immunopathol       Date:  2014-01-17       Impact factor: 9.623

Review 10.  Zebrafish models of dyslipidemia: relevance to atherosclerosis and angiogenesis.

Authors:  Longhou Fang; Chao Liu; Yury I Miller
Journal:  Transl Res       Date:  2013-10-02       Impact factor: 7.012

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.